Skip to main content

Table 3 Mortality and duration of ICU therapy at different time points

From: The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial

 

Patient severity group

Patients (N)

SOFA (points)

Length of stay

(days)

28-day mortality

(N, %)

90-day mortality

(N, %)

Day 4

Total patient population

777

8.4 (4.3)

16 (10–27)

158 (20.3%)

256 (33.9%)

Clinically stable population

145

4.5 (2.4)

8 (6–11)

10 (6.9%)

22 (15.8%)

Clinically stable and low MR-proADM population

79

3.6 (1.5)

8 (7–10)

0 (0.0%)

1 (1.4%)

Actual day-4 discharges

43

3.6 (2.1)

–

1 (2.3%)

4 (10.0%)

Day 7

Total patient population

630

8.0 (4.2)

19 (13–31)

127 (20.2%)

214 (34.9%)

Clinically stable population

124

3.9 (1.7)

11.5 (9–16)

9 (7.3%)

17 (13.9%)

Clinically stable and low MR-proADM population

78

3.4 (1.6)

11 (9–14)

1 (1.3%)

4 (5.3%)

Actual day-7 discharges

36

3.6 (2.6)

–

2 (5.6%)

5 (13.9%)

Day 10

Total patient population

503

7.6 (4.0)

23.5 (17–34.25)

82 (16.3%)

159 (32.6%)

Clinically stable population

85

3.5 (1.8)

15 (13–22)

9 (10.6%)

14 (17.3%)

Clinically stable and low MR-proADM population

57

3.2 (1.3)

14 (12.25–19)

1 (1.8%)

2 (3.8%)

Actual day-10 discharges

29

4.0 (2.6)

–

5 (17.2%)

7 (24.1%)

  1. N number, MR-proADM mid-regional proadrenomedullin, SOFA Sequential Organ Failure Assessment score